fresofol and remifentanil

PreclinicalSmall molecule

fresofol and remifentanil is one of 4 small molecule programs targeting Total Intravenous Anesthesia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Total Intravenous AnesthesiaCompleted

Total Intravenous AnesthesiaPreclinical

Completed

Competition

Competitive Landscape

12 competitors in Total Intravenous Anesthesia

#DrugCompanyPhaseTrials

Anerem

AAcacia Pharma Ltd

Approved

2 2

Ondexxya

UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology

Preclinical

1 3

Ciprofol

Haisco Pharmaceutical Group Co., Ltd.

Preclinical

1 4

fresofol and remifentanil

YYonsei University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Total Intravenous Anesthesia1 trial

Comparison Between Propofol-remifentanil Total Intravenous Anesthesia and Desflurane-remifentanil Balanced Anesthesia With Regard to Post-anesthetic Functional Recovery Measured With QoR-40 in Vitrectomy

Completed·YYonsei University·N/A·NCT02212340·84 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for fresofol and remifentanil. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — fresofol and remifentanil compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for fresofol and remifentanil. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Yonsei University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: YYonsei University

fresofol and remifentanil

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Total Intravenous Anesthesia1 trial

References

Drug Info

Quick Facts

Related News